Group 1: Hong Kong Stocks Performance - Miniso (09896) surged over 20% after reporting a 10% year-on-year increase in adjusted net profit for Q2, with TOP TOY revenue skyrocketing by 87.0% [1] - Li Ning (02331) rose over 6% as it announced a 3.3% year-on-year increase in revenue and declared an interim dividend of HKD 0.3359 per share [1] - Innovent Biologics (02096) increased by over 6% following a 26% year-on-year growth in innovative drug revenue, expanding its commercialized innovative drug portfolio to ten products [1] - Tuhu-W (09690) gained over 10% after reporting a 14.6% year-on-year increase in adjusted net profit while continuing to optimize supply-side costs [1] - Kuaishou-W (01024) rose over 4% with impressive Q2 results and accelerated commercialization [1] - UBTECH (09880) increased over 3% as it led the establishment of two national technical standards for humanoid robots [1] - InnoCare Pharma (02577) saw a rise of over 5% after announcing a partnership with NVIDIA [1] Group 2: Other Notable Performances - China Communications Services (00552) fell over 2% despite a slight 0.18% year-on-year increase in net profit attributable to shareholders, with stable development among its three major clients [2] - Parkson Group (03368) surged nearly 25% after reporting a turnaround to profitability in the first half of the year and proposing an interim dividend of HKD 0.02 per share [2] - Esprit Holdings (00330) jumped over 37% after issuing a profit warning, expecting a net profit of approximately HKD 1 million for the six months ending June 30, 2025 [2] - XPeng Motors (09868) rose over 10% as CEO He Xiaopeng increased his stake by purchasing 3.1 million Class A ordinary shares at an average price of HKD 80.49 per share [2] Group 3: US Market Highlights - Coty (COTY.US) plummeted 21.60% due to weak performance in the US market, retailer destocking, and consumers seeking value, impacting Q4 results [3] - NIO (NIO.US) increased by 9.27% ahead of the launch of its new ES8 product and the start of pre-sales [3] - Huazhu Group (HTHT.US) continued to rise by 2.19% with a 41.3% year-on-year increase in revenue and net profit, benefiting from management franchise and licensing business [3] - Boss Zhipin (BZ.US) rose 6.61% after reporting an over 85% year-on-year increase in net profit for the mid-year and extending its share buyback plan [3] - Youlan Group (YOUL.US) surged 17.13% after announcing plans to acquire four companies to expand its online recruitment and regional market share [3] - Hesai Technology (HSAI.US) increased by 11.00% amid market speculation about a potential IPO in Hong Kong to raise approximately USD 300 million [3] Group 4: Additional US Stock Movements - Miniso (MNSO.US) rose 6.38% after reporting a revenue of CNY 9.39 billion for the first half of the year, a year-on-year increase of 21.1%, with adjusted net profit of CNY 1.28 billion [4] - Walmart (WMT.US) fell 4.49% as Q2 adjusted earnings per share fell short of expectations due to increased insurance claims, legal fees, and restructuring costs [4] - Gilead Sciences (GILD.US) dropped 2.18% after CVS Health decided not to include Gilead's new HIV prevention drug Yeztugo in its business plans [4] - XPeng Motors (XPEV.US) rose 11.68% following the CEO's purchase of 3.1 million Class A ordinary shares [5] - Aegon (AEG.US) increased by 7.64% after reporting a turnaround to profitability in the first half of 2025, primarily driven by growth in its US business [5]

Gilead's shares fell after CVS said it hasn’t yet added its new HIV prevention shot to its commercial drug plans https://t.co/o7NpArMJfd ...

Core Viewpoint - Gilead Sciences (GILD.US) shares fell over 3% to $115.16 following CVS Health's decision not to include Gilead's new HIV prevention drug Yeztugo in its commercial plans due to clinical, financial, and regulatory reasons [1] Group 1: Company Developments - CVS Health's decision is based on clinical, financial, and regulatory factors [1] - Gilead is still in negotiations with CVS regarding Yeztugo [1] Group 2: Product Pricing and Market Goals - The annual list price for Yeztugo in the U.S. exceeds $28,000 [1] - Gilead aims to achieve 75% coverage by U.S. insurers by the end of the year and 90% coverage by June 2026 [1]

Group 1 - The analysis focuses on Gilead Sciences Inc. (NASDAQ: GILD) and has maintained a bullish outlook on the company and its stock over several years [1] - The investment strategy emphasizes high-quality companies that can outperform the market in the long run due to competitive advantages and defensibility [1] - The analysis covers companies across various market capitalizations, specifically in European and North American markets [1] Group 2 - The analyst has a beneficial long position in Gilead Sciences shares through stock ownership, options, or other derivatives [2] - The article expresses the analyst's own opinions and is not influenced by compensation from any company mentioned [2]

Group 1 - The article provides a top-down analysis of the healthcare sector, focusing on industry metrics related to value, quality, and momentum [1] - It aims to assist in analyzing ETFs such as the Health Care Select Sector SPDR ETF [1] - The author, Fred Piard, has over 30 years of experience in technology and has been investing in data-driven systematic strategies since 2010 [1] Group 2 - The article does not provide specific financial data or performance metrics related to individual companies within the healthcare sector [2][3]

Core Insights - Gilead Sciences, Inc. (GILD) shares increased by 7.3% following strong Q2 2025 results and an upward revision of its annual guidance for 2025 [1][2] - Adjusted EPS was $2.01, surpassing the Zacks Consensus Estimate of $1.95, while total revenues reached $7.1 billion, exceeding the estimate of $6.9 billion, marking a 2% year-over-year growth [1][2] Financial Performance - Gilead raised its full-year product sales and EPS guidance, driven by robust demand for HIV treatments, particularly Biktarvy and Descovy [2] - Year-to-date, GILD's stock has risen 28.2%, outperforming the industry average gain of 3.7% [2] HIV Franchise Strength - The HIV treatment portfolio showed a strong performance with a 7% year-over-year growth, largely due to Biktarvy's sales growth of 9% to $3.5 billion [6][8] - Descovy's sales for pre-exposure prophylaxis (PrEP) surged 35% year-over-year to $653 million, marking its strongest quarter [7] - Gilead anticipates approximately 3% growth in HIV sales for 2025, up from previous flat growth expectations [7] New Product Launches - The FDA approved lenacapavir, branded as Yeztugo, enhancing Gilead's HIV portfolio amid competition from generics [9] - Yeztugo, a long-acting injectable PrEP, is expected to address barriers to broader PrEP adoption [10] - Gilead aims for up to eight additional HIV product launches by the end of 2033, with five expected by the end of 2030 [11] Oncology Portfolio - Trodelvy, a breast cancer drug, saw a 14% year-over-year sales increase to $364 million, outperforming estimates [12] - Gilead is pursuing approval for Trodelvy in first-line treatment settings based on trial results [13] Challenges in Other Franchises - The Cell Therapy franchise faced a 7% sales decline to $485 million due to competitive pressures [14] - Liver Disease portfolio sales decreased by 4% to $795 million, primarily due to lower chronic hepatitis C virus sales impacted by Medicare Part D redesign [15][16] Valuation and Estimates - GILD shares trade at a forward P/E ratio of 14.18, slightly below the large-cap pharma industry average of 14.45 [17] - Earnings estimates for 2025 have increased to $8.09 from $7.92 over the past month [18] Strategic Outlook - Gilead's innovation in the HIV portfolio and the approval of Yeztugo are seen as significant growth drivers [21] - Collaborations, such as with Merck for HIV treatment, and strategic acquisitions are viewed positively [22] - The company maintains a strong cash position, with $7.1 billion in cash and equivalents, supporting a sustainable dividend yield of 2.67% [25]

Core Insights - The strategic cooperation agreement between China National Pharmaceutical Group (Sinopharm) and Gilead Sciences aims to enhance the accessibility of innovative antiviral drugs for chronic hepatitis B patients in China [1][2] - Approximately 86 million hepatitis B virus carriers exist in China, accounting for about one-third of the global infected population [1] - The new antiviral drug, Vemlidy (TAF), was launched in China in 2018 and has been included in the national medical insurance directory, making it more affordable for patients [2] Group 1 - The partnership will leverage Sinopharm's extensive network and marketing capabilities to improve the availability of Vemlidy in grassroots markets [1] - Chronic hepatitis B poses significant health risks, including liver cirrhosis and liver cancer, but advancements in antiviral medications have provided safer treatment options with low resistance rates [1] - Gilead Sciences has introduced eight global innovative drugs in China since 2017, focusing on improving drug accessibility through insurance and collaborations [2] Group 2 - Sinopharm's president emphasized the importance of brand, channel, and network advantages in increasing the medical coverage of Vemlidy for more hepatitis B patients [2] - The collaboration marks a new chapter in the ongoing partnership between Sinopharm and Gilead Sciences, which has previously involved a series of import agency collaborations [2]

Core Viewpoint - Gilead Sciences experienced a significant stock price increase of 8.28% following the release of its Q2 2025 financial results, driven by strong financial performance, the successful launch of the breakthrough HIV prevention drug Yeztugo, and ongoing diversification of its pipeline [1][3]. Financial Performance - Total revenue reached $7.08 billion, reflecting a 2% year-over-year growth, slightly below market expectations. Product sales amounted to $7.05 billion, also up 2%, with a 4% increase to $6.93 billion when excluding Veklury [4][7]. - GAAP earnings per share (EPS) were $1.56, a 21% increase from $1.29 in Q2 2024. Non-GAAP EPS remained stable at $2.01, primarily impacted by increased R&D expenses [4][6]. Business Segments Performance HIV Business - HIV product sales totaled $5.09 billion, a 7% increase year-over-year, accounting for 72% of total revenue. Biktarvy sales reached $3.5 billion, while Descovy saw a 35% increase to $653 million due to price hikes and increased demand [8][10]. - Yeztugo, the first long-acting HIV prevention drug, received FDA approval and is expected to launch in the second half of 2025, with plans to provide 2 million doses to low-income countries [9][18]. Liver Disease Business - Liver disease product sales were $795 million, down 4% year-over-year, primarily due to declining HCV revenues amid market shrinkage and generic competition. Livdelzi showed significant growth, although specific figures were not disclosed [12][13]. Oncology Business - Oncology product sales reached $849 million, a 1% increase. Trodelvy sales grew by 14% to $364 million, driven by increased demand. However, CAR-T therapies faced challenges, with overall sales declining by 7% [14][15]. Other Products - Veklury sales plummeted by 44% to $121 million due to decreased COVID-19 hospitalization rates. Other products generated $202 million, down 28% [16][17]. Guidance and Future Outlook - Gilead raised its full-year guidance, projecting product sales between $28.3 billion and $28.7 billion, up from previous estimates. GAAP EPS is now expected to be between $5.85 and $6.15 [5][24]. - The company remains optimistic about Yeztugo's market acceptance and the potential for growth in its HIV product line, while also acknowledging policy risks and market competition [25][26]. Key R&D Milestones - Yeztugo's FDA approval and WHO guideline recommendation mark significant advancements in the HIV field. However, some candidates faced clinical holds, impacting development timelines [18][19]. - Livdelzi's long-term safety data supports its potential in liver disease, while Trodelvy's positive trial results may expand its market [20][21]. Cost Control and Operational Efficiency - Non-GAAP gross margin improved to 86.9%, benefiting from product mix optimization. R&D expenses increased by 9% to $1.5 billion, driven by clinical manufacturing and research activities [21][22].

Core Viewpoint - Investor sentiment is highly pessimistic, and U.S. pharmaceutical stocks are facing the most severe challenges in decades [1][3]. Group 1: Market Performance - Major biopharmaceutical companies experienced significant sell-offs during the recent earnings season, leading to a weak overall performance of the sector [1][3]. - The healthcare sector's weight in the S&P 500 index has dropped to its lowest point in decades [1][9]. - Vertex Pharmaceuticals and Eli Lilly faced substantial declines, with Vertex dropping 20.6% on August 4 due to setbacks in its pain medication project, while Eli Lilly recorded its largest drop since the dot-com bubble [4][7]. Group 2: Stock Volatility - The average volatility of healthcare stocks during this earnings season reached ±6%, marking one of the highest volatility records in history [3][9]. - Other major healthcare stocks, including Novo Nordisk, McKesson Corp, and UnitedHealth Group, saw declines of 10% to 20% post-earnings [3][7]. Group 3: Policy Uncertainty - Policy uncertainties, particularly regarding the Trump administration's Most Favored Nation pricing proposal and potential tariffs on the pharmaceutical industry, are major challenges for pharmaceutical stocks [8][9]. - Analysts are closely monitoring the potential announcement of pharmaceutical tariffs, expected in mid-August, which could further impact the sector [8][9]. Group 4: Company-Specific Developments - Despite the overall weak performance, some companies like Johnson & Johnson and Gilead Sciences showed strong results, with Gilead's stock rising 6% last week and a year-to-date increase of 30% due to robust HIV business growth [7]. - The weight loss drug sector has been particularly hard hit, with Eli Lilly losing $100 billion in market value due to disappointing data on its oral weight loss medication [7].

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **Biopharma** industry in **North America** with a comprehensive analysis of the **US drug market** as per **IQVIA Rx** data [1][6]. Core Insights - The **Total Prescription Year-over-Year (YoY) growth** for the week ending August 1, 2025, was reported at **+2.8%**, an increase from **+1.7%** the previous week and **+2.6%** over the past 12 weeks [1][6]. - For the week ended August 1, the **US total market weekly TRx YoY change** was **+2.8%**, compared to **+0.9%** a year ago. The **rolling 4-week TRx YoY** was **+2.9%** and the **rolling 12-week TRx YoY** was **+2.6%** [2]. Company-Specific Developments - **Bristol Myers Squibb (BMY)**: - The drug **Cobenfy** was approved for schizophrenia on September 26, 2024. The current scripts are approximately **2,010** for the week, up from **1,950** the previous week. To meet 2025 consensus expectations, Cobenfy's TRx needs to track at **~2-3x** the volumes from recent schizophrenia launches [3]. - The consensus estimate for Cobenfy has decreased from **$196 million** to **$171 million**, implying that approximately **129K TRx** are required to meet these estimates [3]. - **Vertex Pharmaceuticals (VRTX)**: - The drug **Journavx** was approved for acute pain on January 30, 2025, with current scripts at approximately **6,800**, up from **6,430** the previous week. It is noted that hospital scripts, which account for about **35%** of total scripts, are not captured by IQVIA [4]. - To achieve a sales target of **$78 million**, approximately **345K total scripts** are needed, assuming a **$225 net price per script** [4]. - **Gilead Sciences (GILD)**: - The launch comparison for **Yeztugo** (lenacapavir) shows current TRx at approximately **210**, down from **300** the previous week. The injectable formulation accounts for **50%** of total TRx [5]. Additional Insights - The **extended unit (EUTRx)** weekly YoY growth was reported at **+1.9%**, which is below the TRx YoY growth [2]. - The **sequential weekly TRx growth** was **-0.1%**, an improvement from **-1.2%** the week before [2]. - The **biopharma industry view** is categorized as **attractive**, while the major pharmaceuticals industry view is **in-line** [7]. Notable Trends - The **momentum of top outpatient drugs** indicates varying performance across different companies, with notable declines in some established drugs like **Humira** (AbbVie) showing a **-40%** YoY change, while newer drugs like **Mounjaro** (Eli Lilly) and **Zepbound** (Eli Lilly) show significant growth rates of **69%** and **257%** respectively [24]. Conclusion - The conference call highlights a positive trend in the US drug market with specific growth in total prescriptions. However, individual company performance varies significantly, with newer drugs showing strong growth potential while established drugs face declines. The insights provided can guide investment decisions in the biopharma sector.